The reduction of (3S)-N,N-dibenzylamino-2-ketophosphonate 5 derived from L-leucine with catecholborane at -20 o C afford the (3S)-N,N-dibenzylamino-(2R)-hydroxyphosphonate syn-6, whereas the reduction of (3S)-N-benzylamino-2-ketophosphonate 9 with Zn(BH 4 ) 2 at -78 o C gave the (3S)-N-benzylamino-(2S)-hydroxyphosphonate anti-10. The reduction in both cases was in good chemical yields and high diastereoselectivity. The hydrolysis and hydrogenolysis of syn-6 and anti-10 gave phosphostatine 12 and phosphoepistatine 13, respectively.
Introduction
(4S)-Amino-(3S)-hydroxy-6-methylheptanoic acid (Statine) 1, a nonproteinogenic amino acid, is a key component of pepstatin, a natural hexapeptide antibiotic isolated by Umezawa and coworkers from various species of actinomices. 1 Additionally, (-)-statine 1 has attracted a lot of interest because of its potential use in the treatment of hypertension, congestive heart failure, malaria and Alzheimer's disease. For these reasons, many synthetic routes toward statine 1 and their analogues have been developed. 2 On the other hand, phosphonates and phosphinates functionalized with amino and hydroxy groups have attracted considerably attention in recent years for their role in biologically relevant processes such as inhibition of rennin and HIV protease, human calpain I and their use as haptens in the development of catalytic antibodies. 3 In particular, γ-amino-β-hydroxyphosphonic (LVRs) in the angiotensin II, providing a more potent inhibitory activity for rennin over porcine pepsin and bovine cathepsin D. 6 As a result, numerous synthetic methods for chiral non-racemic β-amino-α-hydroxyphosphonic 2 have been developed. 7 However, to the best of our knowledge, only a few synthetic approaches to obtain optically active esters of 3-amino-2-hydroxyphosphonic acid 3 have been described in the literature, which involve the reaction of the anion of methylphosphonate with α-aminoaldehydes, 5, 6 and the catalytic asymmetric aminohydroxylation of β,γ-unsaturated phosphonates, 7f but in both methodologies the yields and diastereoselectivities remain low. Recently, Yokomatsu et al. 8 described the synthesis of 3-amino-2-hydroxyphosphonates with an improved diastereoselectivity via the dihydroxylation of β,γ-unsaturated phosphonates and the subsequent regioselective amination of their cyclic sulfates. 
Results and Discussion
(3S)-N,N-Dibenzylamino-2-ketophosphonate 5 was synthesized in two steps from L-leucine (Scheme 1). Thus, the first step of the synthesis was the tribenzylation of L-leucine with excess of benzyl bromide and K 2 CO 3 under reflux in a mixture of MeOH:H 2 O, obtaining the corresponding (S)-N,N-dibenzylleucine benzyl ester 4 in 77% yield. 11 Then, the resulting benzyl ester 4 was treated with the lithium salt of dimethyl methylphosphonate at -78 oC in THF, to obtain the (3S)-N,N-dibenzylamino-2-ketophosphonate 5 in 98% yield. Having efficiently prepared the 2-ketophosphonate 5, we turned our attention to the diastereoselective reduction of the carbonyl group to obtain the (3S)-N,N-dibenzylamino-2-hydroxyphosphonates 6 and 7. The reduction was carried out using NaBH 4 , Zn(BH 4 ) 2 and catecholborane as reducing agents. Conditions, yields and diastereomeric ratio are summarized in Table 1 . than that the diastereomer anti-7 (35.37 ppm). The absolute configuration of the new stereogenic center in syn-6 and anti-7 was assigned by analogy with other (3S)-N,N-dibenzylamino-2-hydroxyphosphonates. 10 Therefore, we propose that the reduction of 5 with catecholborane took place under non-chelation control or Felkin-Ahn model, 13 and that the bulkyness of the N,N-dibenzylamino group is sufficient to simultaneously limit the rotamer populations around the hinge bounds adjacent to the carbonyl group blocking the re face of carbonyl group and, thereby allowing the addition of hydride to take in a diastereoselective manner ( Figure 1a ). On the other hand, the reduction of 5 with Zn(BH 4 ) 2 seems to proceed in such way that the metal ions do not bind sufficiently strongly to the N,N-dibenzylamino and keto groups to induce chelation controlled reaction ( Figure 1b ). It was expected that the zinc ions would provide increased conformational control and hence higher diastereoselectivity toward the 2-hydroxyphosphonate anti-7; however, In order to induce the formation of anti-3-amino-2-hydroxyphosphonate, now we turned to the preparation of (3S)-N-benzylamino-2-ketophosphonate 9 (Scheme 2). 17 Thus, the starting (S)-N-benzylleucine methyl ester 8 was prepared by treatment of the corresponding amino methyl ester hydrochloride with K 2 CO 3 and benzyl bromide in acetonitrile at room temperature. Then, the methyl ester 8 was treated with the lithium salt of dimethyl methylphosphonate at -78 o C in THF, to afford the corresponding (3S)-N-benzylamino-2-ketophosphonate 9 (Scheme 2).
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Scheme 2
Just as we have previously described, 17 the reduction of 9 using Zn(BH 4 ) 2 at -78 o C in THF afforded the corresponding 3-N-benzylamino-2-hydroxyphosphonates anti-10 and syn-11 in good chemical yield and with high diastereoselectivity, with a predominance of the desired anti product (Scheme 3). acid, that without any further purification was treated with palladium on carbon in methanol under hydrogen gas atmosphere at room temperature, obtaining the phosphostatine 12 and phosphoepistatine 13, in 89% and 93% yield, respectively, (Scheme 4). 
Scheme 4
In conclusion, we have found a new methodology for the preparation of phosphostatine and phosphoepistatine diastereomerically pures. Additionally, the conditions described in this paper, make this experimental operation a good and simple method to obtain the 3-amino-2-hydroxyphosphonates syn and anti in high diastereoselectivity changing the protective group on the nitrogen atom of L-amino acid.
Experimental Section
General Procedures. Optical rotations were taken on a Perkin-Elmer 241 polarimeter in a 1 dm tube; concentrations are given in g/100 mL. For flash chromatography, silica gel 60 (230-400 mesh ASTM, Merck) was used. 
Dimethyl (3S)-(3-N,N-dibenzylamino-5-methyl-2-oxohexylphosphonate 5.
12 A solution of dimethyl methylphosphonate (2.81 g, 22.7 mmol) in anhydrous THF (40 mL) was cooled at -78 o C before the slow addition of n-BuLi 2.5 M in hexanes (9.7 mL, 23.3 mmol). The resulting solution was stirred at -50 o C for 1.5 h and then cooled to -78 o C. To this mixture was slowly added a solution of benzyl ester 4 (2.6 g, 6.5 mmol) in dry THF (45 mL). The reaction mixture was stirred at -78 o C for 4 h before the addition of a saturated solution of NH 4 Cl. The solvent was evaporated under reduced pressure, the residue was dissolved in water (30 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and evaporated under reduced pressure. C under a nitrogen atmosphere with bromotrimethylsilane (361 mg, 0.31 mL, 2.36 mmol). The reaction mixture was stirred at room temperature for 6-8 h, and after this period of time the volatile materials were evaporated under reduced pressure, water was then added. After 30 min. the solvents were evaporated in vacuo to give (3S)-N,N-dibenzylamino-(2R)-hydroxyphosphonic acid, which without isolation were treated with palladium on carbon (5 % wt) 225 mg in methanol (10 mL) and stirred for 12 h under a hydrogen gas atmosphere at room temperature. The mixture was filtered through a pad of celite, and the solvent was evaporated under reduced pressure. The residue was treated with propylene oxide (5 mL) to give the title compound as a white solid (201 mg, 89% yield Amino-(2S)-hydroxy-5-methylhexylphosphonic acid (phosphoepistatine) (13) . In an identical manner, the 2-hydroxyphosphonate anti-10 (350 mg, 1.06 mmol) was treated with bromotrimethylsilane (357 mg, 0.31 mL, 2.33 mmol) followed by palladium on carbon (10 % wt) (175 mg) in methanol (10 mL) and propylene oxide (5 mL) to give the title compound as a white solid (208 mg, 93% yield). m. 
